Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.58 |
| ▸ | CNR2 | P34972 | 9/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4910813 | 0.92 | PDE4B (0.54) | CNR1CNR2PDE4B | |
| SCHEMBL4634312 | 0.91 | CNR1 (0.53) | CNR1PDE4BCYP19A1 | |
| SCHEMBL4633677 | 0.90 | PDE4B (0.52) | CNR1PDE4B | |
| SCHEMBL974512 | 0.90 | PDE4B (0.54) | CNR1CNR2PDE4BCYP19A1 | |
| SCHEMBL5484151 | 0.90 | PDE4B (0.54) | CNR1CNR2PDE4BCYP19A1 | |
| SCHEMBL10057707 | 0.89 | NPSR1 (0.64) | CNR1CNR2CYP19A1 | |
| SCHEMBL4816797 | 0.89 | PDE4B (0.53) | CNR1CNR2PDE4BCYP19A1 | |
| SCHEMBL4695480 | 0.89 | PDE4B (0.53) | CNR1CNR2PDE4BCYP19A1 | |
| SCHEMBL29838956 | 0.89 | CNR2 (0.71) | CNR1CNR2 | |
| SCHEMBL923180 | 0.89 | CNR2 (0.71) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015162452-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CB1 RECEPTOR ANTAGONISTS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2015-10-29 | — | — | WO | disclosed |
| EP-2121617-B1 | CB1 RECEPTOR MODULATORS | 7TM PHARMA AS (DK) | 2014-01-22 | — | — | EP | disclosed |
| EP-2121617-B1 | CB1 RECEPTOR MODULATORS | 7TM PHARMA AS (DK) | 2014-01-22 | — | — | EP | disclosed |
| EP-2121659-B1 | MODULATORS OF CB1 RECEPTORS | 7TM PHARMA AS (DK) | 2013-05-15 | — | — | EP | disclosed |
| EP-2121659-B1 | MODULATORS OF CB1 RECEPTORS | 7TM PHARMA AS (DK) | 2013-05-15 | — | — | EP | disclosed |
| US-8173680-B2 | Cannabinoid receptor modulators | 7TM PHARMA A/S (DK) | 2012-05-08 | — | — | US | disclosed |
| US-8173680-B2 | Cannabinoid receptor modulators | 7TM PHARMA A/S (DK) | 2012-05-08 | — | — | US | disclosed |
| US-8148404-B2 | Modulators of CB1 receptors | 7TM PHARMA A/S (DK) | 2012-04-03 | — | — | US | disclosed |
| US-8148404-B2 | Modulators of CB1 receptors | 7TM PHARMA A/S (DK) | 2012-04-03 | — | — | US | disclosed |
| US-8148404-B2 | Modulators of CB1 receptors | 7TM PHARMA A/S (DK) | 2012-04-03 | — | — | US | disclosed |
| US-20060205948-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2006-09-14 | — | — | US | disclosed |
| EP-1622909-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1572662-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS AND USES THEREOF | Pfizer Products Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004094429-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040214855-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | disclosed |
| US-20040214855-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | disclosed |
| US-20040214855-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | disclosed |
| WO-2004052864-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040122074-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-06-24 | — | — | US | disclosed |
| US-20040077650-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077650-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885PDE4B 2564/4885 |
| US-20040122074-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885PDE4B 2656/4885 |
| US-20060205948-A1 | Cannabinoid receptor ligands and uses thereof | CNR2, CNR1, GPR18 | CNR1 2/4885CNR2 1/4885PDE4B 2135/4885 |
| US-20040214855-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885PDE4B 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.